Search research articles
Contact Us
Filters
Showing results (31-40 of 63) with videos related to
Page
of 7
Sort By:
American Journal of Hematology
|
August 16, 2023
The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL
Kai Rejeski, Yucai Wang, Omar Albanyan, et al.
Hemasphere
|
December 10, 2025
Outcomes and treatment patterns of patients with primary mediastinal B-cell lymphoma after CAR-T cell therapy failure: A DESCAR-T analysis
Jean Galtier, Pierre Sesques, Vivien Dupont, et al.
Journal of Hematology & Oncology
|
July 31, 2023
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
Kai Rejeski, Doris K Hansen, Radhika Bansal, et al.
Cancers
|
March 6, 2021
Apoptotic Blocks in Primary Non-Hodgkin B Cell Lymphomas Identified by BH3 Profiling
Ryan N Rys, Claudia M Wever, Dominique Geoffrion, et al.
Blood Advances
|
August 24, 2021
Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified
Estelle Bourbon, Delphine Maucort-Boulch, Juliette Fontaine, et al.
Blood
|
February 26, 2026
Patient-Derived Lymphoma Spheroids Reveal Predictive Markers of Glofitamab Resistance in Relapsed/Refractory B-NHL
Paul Marcoux, Fabien Gava, Marie Tosolini, et al.
Nature Cancer
|
April 3, 2025
Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study
Guillaume Cartron, Roch Houot, Yassine Al Tabaa, et al.
Blood Advances
|
September 6, 2023
Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry
Jean Lemoine, Emmanuel Bachy, Guillaume Cartron, et al.
Blood
|
September 19, 2022
Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis
Roberta Di Blasi, Steven Le Gouill, Emmanuel Bachy, et al.
Haematologica
|
May 21, 2026
Prolonged survival with glofitamab in non-diffuse large B-cell lymphoma after CAR T-cell therapy relapse
Pierre Sesques, Roch Houot, Yassine Al Tabaa, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 63) with videos related to
Sort By:
Page
of 7
American Journal of Hematology
|
August 16, 2023
The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL
Kai Rejeski, Yucai Wang, Omar Albanyan, et al.
Hemasphere
|
December 10, 2025
Outcomes and treatment patterns of patients with primary mediastinal B-cell lymphoma after CAR-T cell therapy failure: A DESCAR-T analysis
Jean Galtier, Pierre Sesques, Vivien Dupont, et al.
Journal of Hematology & Oncology
|
July 31, 2023
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
Kai Rejeski, Doris K Hansen, Radhika Bansal, et al.
Cancers
|
March 6, 2021
Apoptotic Blocks in Primary Non-Hodgkin B Cell Lymphomas Identified by BH3 Profiling
Ryan N Rys, Claudia M Wever, Dominique Geoffrion, et al.
Blood Advances
|
August 24, 2021
Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified
Estelle Bourbon, Delphine Maucort-Boulch, Juliette Fontaine, et al.
Blood
|
February 26, 2026
Patient-Derived Lymphoma Spheroids Reveal Predictive Markers of Glofitamab Resistance in Relapsed/Refractory B-NHL
Paul Marcoux, Fabien Gava, Marie Tosolini, et al.
Nature Cancer
|
April 3, 2025
Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study
Guillaume Cartron, Roch Houot, Yassine Al Tabaa, et al.
Blood Advances
|
September 6, 2023
Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry
Jean Lemoine, Emmanuel Bachy, Guillaume Cartron, et al.
Blood
|
September 19, 2022
Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis
Roberta Di Blasi, Steven Le Gouill, Emmanuel Bachy, et al.
Haematologica
|
May 21, 2026
Prolonged survival with glofitamab in non-diffuse large B-cell lymphoma after CAR T-cell therapy relapse
Pierre Sesques, Roch Houot, Yassine Al Tabaa, et al.
Page
of 7